Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 4/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 9/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12584952 | 0.92 | CCR2 (0.38) | PTGER4PTGDRCCR2CYP3A5KCNH2 | |
| SCHEMBL987689 | 0.90 | PTGER4 (0.40) | PTGER4PTGDRCYP3A5MMP12 | |
| SCHEMBL987832 | 0.87 | CCR2 (0.49) | PTGER4PTGDRCCR2CYP3A5KCNH2 | |
| SCHEMBL988181 | 0.84 | VCP (0.38) | PTGER4PTGDRCNR2 | |
| SCHEMBL12585950 | 0.83 | PTGER4 (0.42) | PTGER4PTGDRCCR2CYP3A5CNR2 | |
| SCHEMBL12584947 | 0.82 | KDM4E (0.43) | PTGER4PTGDRCYP3A5CYP2C9CYP1A2 | |
| SCHEMBL12584927 | 0.81 | RAB9A (0.40) | PTGER4CCR2CYP3A5KCNH2CACNA1I | |
| Bicarbonate SCHEMBL16143667 | 0.81 | NPC1 (0.43) | PTGER4PTGDRCYP3A5CNR2CYP3A4 | |
| SCHEMBL12585911 | 0.80 | PTGER4 (0.43) | PTGER4PTGDRCCR2CYP3A5KCNH2 | |
| SCHEMBL12584009 | 0.79 | CCR2 (0.47) | PTGER4PTGDRCCR2CYP3A5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565191-B1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | ASTELLAS PHARMA INC (JP) | 2014-10-08 | — | — | EP | claimed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | claimed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | claimed |
| EP-2565191-B1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | ASTELLAS PHARMA INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGDR 13/4885CCR2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.